Vertex Pharmaceuticals price target raised to $486 from $480 at Scotiabank
The Fly

Vertex Pharmaceuticals price target raised to $486 from $480 at Scotiabank

Scotiabank analyst Greg Harrison raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $486 from $480 and keeps a Sector Perform rating on the shares. The company posted a beat and raise for Q3, with total revenues coming above consensus, the analyst tells investors. The firm sees “a lot to like” with the company’s story, given the strong commercial execution and approval of Vanza triple in cystic fibrosis and suzetrigine in acute paint expected January.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App